IL-17C as a Driver of Inflammation in Psoriasis
- 23 September 2025
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5451-5467
Abstract
In psoriatic lesions, interleukin (IL)-17C protein expression has been reported as high as 125 times that of IL-17A; as such, it is crucial to understand the role that IL-17C plays in psoriasis, inflammation, and treatment response. Overexpression or injection of IL-17C in mice results in increased epidermal thickening and inflammation, whereas psoriatic mice with IL-17C knockout have decreased disease severity compared with control littermates. In psoriasis, IL-17C likely acts as a critical inflammatory amplifier via a feed-forward mechanism, wherein IL-17-producing CD4+ helper T (TH17) cells and IL-17-producing CD8+ cytotoxic T (TC17) cells stimulate IL-17C expression in keratinocytes. Then, keratinocyte-derived IL-17C induces IL-17A expression in TH17 and TC17 cells. Additionally, keratinocyte-derived IL-17C propagates its own signaling in an autocrine manner. Furthermore, studies suggest that IL-17C acts as an early mediator of psoriasis. No approved therapies directly target IL-17C. Brodalumab is an IL-17 receptor (IL-17R) A antagonist that inhibits IL-17A, F, C, and E signaling and has a unique mechanism of action among biologic therapies for psoriasis. By way of IL-17RA blockade, brodalumab is the only approved therapy for psoriasis that inhibits IL-17C signaling. This unique mechanism of action is hypothesized to correlate with efficacy in patients with prior failures to anti–IL-17A therapies and relatively higher rates of early skin clearance compared with those of other biologic therapies. Clinical studies are needed to confirm these correlations. In summary, IL-17C is an inflammatory amplifier and early psoriatic mediator, and inhibition of IL-17C may be beneficial in psoriasis management.Keywords
Funding Information
- Bausch Health Companies Inc.
This publication has 67 references indexed in Scilit:
- IL-17C in human mucosal immunity: More than just a middle childCytokine, 2021
- A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmDermatology and Therapy, 2021
- Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitorsJournal of the American Academy of Dermatology, 2021
- Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedJournal of the American Academy of Dermatology, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbiditiesJournal of the American Academy of Dermatology, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective studyArchives of Dermatological Research, 2019
- IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory diseaseImmunology Letters, 2016
- Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor EImmunity, 2011
- Interleukin-17 Family Members and InflammationImmunity, 2004